ClinicalTrials.gg
RecruitingNCT05444920ITA-WebNetUpdated Mar 27, 2026

The Italian Transthyretin Amyloidosis Web-Network

An observational study in ATTR Amyloidosis, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Recruiting at 30 sites in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Observational

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,000
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Amyloidosis with a site in Italy — 14 open to participants now, 17 under way, 7 of them phase 3. Amyloidosis · Italy.

Planned enrollment
5th of 14
1,000 · median 365
Started
2022
with 5 others
Observational
14 of 52
7 open now
Primary completion
2026-12
later than 3 of 16 live
Registered
37th of 52
by date
Lead sponsor
8 of 52
Fondazione IRCCS Policlinico San Matteo di Pavia

Among the 52 studies in Amyloidosis with a site in Italy, this one is the 5th largest by planned enrollment of the 14 observational ones that give a count, is one of 6 that started in 2022, is one of 14 observational ones, reaches primary completion later than 3 of the 16 other live ones, and was the 37th registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

14 of the 52 studies in Amyloidosis with a site in Italy are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Amyloidosis with a site in Italy, or all of them as a file.
02

Study summary

The study aims, by generating a large registry of patients with ATTR amyloidosis, including data at diagnosis and during follow up, to describe the natural history of ATTR amyloidosis in a real-world setting and to define and validate prognostic models, response criteria applicable at any point of the disease. The registry will also be used for data sharing and to allow the possibility of a close collaboration amongst the amyloidosis experts of the ARTC and all the physicians around the Country involved in the diagnosis and management of systemic amyloidosis. Thanks to the online registry, the diagnostic facility of the ARTC will be made available to requesting physicians.

03

Conditions studied

  • ATTR Amyloidosis

Keywords

  • amyloidosis
  • systemic amyloidosis
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be entered the database pending on expressing an informed consent of the use of their data for research purposes. Data of deceased patients will be used only if they have expressed their consent to the use of their clinical data

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Suspected diagnosis of systemic and localized amyloidosis;
  2. age .18 years;
  3. ability to understand and willingness to sign an (patients who already sign informed consent for clinical data to be used in retrospective analyses will be accepted);
  4. planned (or ongoing) follow-up at participating center.

Exclusion criteria

Exclusion Criteria:

1. Diagnosis of light chain (AL) amyloidosis

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Establishing an online tool for data-sharing, available for health care providers

    Different data (types type of organ involvement, biomarkers of organ damage, date of onset of symptoms, date of diagnosis, type of treatment (if any)) will be shared between the health-care professionals and the panel of experts.

    Time frame: 5 years

07

Study locations

1 of 30 sites recruiting
  • ASST Ovest Milanese - Ospedale di Legnano
    Legnano, MI, Italy
    Not yet recruiting
    • Corinna Antonia Inserra, MD · Contact
  • AOU San Luigi Gonzaga
    Orbassano, TO, Italy
    Not yet recruiting
    • Carloalberto Biolè, MD · Contact
  • AOU Ospedali Riuniti
    Ancona, Italy
    Not yet recruiting
    • Fabio Vagnarelli, MD · Contact
  • Policlinico di Bari
    Bari, Italy
    Not yet recruiting
    • Rita Rizzi, MD · Contact
  • ASST Papa Giovanni XXIII
    Bergamo, Italy
    Not yet recruiting
    • Emilia D'Elia, MD · Contact
  • ASST Spedali Civili di Brescia
    Brescia, Italy
    Not yet recruiting
    • Daniela Tomasoni, MD · Contact
  • Ospedale Oncologico "Armando Businco"
    Cagliari, Italy
    Not yet recruiting
    • Daniele Derudas, MD · Contact
  • Azienda Ospedaliera di Cosenza
    Cosenza, Italy
    Not yet recruiting
    • Enrica Martino, MD · Contact
  • Presidio ospedaliero di Ivrea
    Ivrea, Italy
    Not yet recruiting
    • Walter Grosso Marra, MD · Contact
  • Asst Santi Paolo E Carlo
    Milan, Italy
    Not yet recruiting
    • Vittorio Montefusco, MD · Contact
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milan, Italy
    Not yet recruiting
    • Gloria Santangelo, MD · Contact
  • IRCCS Istituto Clinico Humanitas
    Milan, Italy
    Not yet recruiting
    • Giuseppe Pinto, MD · Contact
  • Istituto Auxologico Italiano
    Milan, Italy
    Not yet recruiting
    • Francesco Perelli, MD · Contact
  • Istituto Monzino
    Milan, Italy
    Not yet recruiting
    • Mauro Contini, MD · Contact
  • IRCCS San Gerardo Monza
    Monza, Italy
    Not yet recruiting
    • Daniela Pini, MD · Contact
  • 'Azienda Ospedale. Università di Padova
    Padova, Italy
    Not yet recruiting
    • Alberto Cipriani, MD · Contact
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
    Recruiting
  • Azienda Ospedaliera di Perugia
    Perugia, Italy
    Not yet recruiting
    • Cinzia Zuchi, MD · Contact
  • Ospedale Civile ASL Pescara
    Pescara, Italy
    Not yet recruiting
    • Roberta Magnano, MD · Contact
  • Azienda Ospedaliera Sant'Andrea
    Roma, Italy
    Not yet recruiting
    • Beatrice Musumeci, MD · Contact
  • Ematologia ASL Roma 1
    Roma, Italy
    Not yet recruiting
    • Tommaso Caravita, MD · Contact
  • Fondazione Policlinico Universitario Agostino Gemelli CARDIOLOGIA
    Roma, Italy
    Not yet recruiting
    • Francesca Graziani, MD · Contact
  • Policlinico Universitario Agostino Gemelli NEUROLOGIA
    Roma, Italy
    Not yet recruiting
    • Marco Luigetti, MD · Contact
  • Plesso Ospedaliero "Andrea Tortora" di Pagani
    Salerno, Italy
    Not yet recruiting
    • Catello Califano, MD · Contact
  • Azienda Ospedaliero Universitaria di Sassari
    Sassari, Italy
    Not yet recruiting
    • Giuseppe Damiano Sanna, MD · Contact
  • Azienda Ospedaliero Universitaria Senese
    Siena, Italy
    Not yet recruiting
    • Elisa Giacomin, MD · Contact
  • Ospedale San Giovanni Bosco
    Torino, Italy
    Not yet recruiting
    • Piera Costanzo, MD · Contact
  • l'Ospedale di Treviglio-Caravaggio
    Treviglio, Italy
    Not yet recruiting
    • Giovanna Faggiano, MD · Contact
  • Osp. Sant'Andrea
    Vercelli, Italy
    Not yet recruiting
    • Lorenzo De Paoli, MD · Contact
  • Azienda Ulss 8 Berica
    Vicenza, Italy
    Not yet recruiting
    • Edoardo Scomazzon, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Dec 2026, 53 months after the start.

Of 52 observational studies under Amyloidosis, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 183. This study's planned 53 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2022
First posted
Jul 6, 2022
StartActual
Jul 13, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Nov 1, 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05444920
Responsible party
Paolo Milani (Principal Investigator, Fondazione IRCCS Policlinico San Matteo di Pavia) — Principal investigator
First posted
Jul 6, 2022
Start date
Jul 13, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

Paolo Milani, MD, PhD
Contact
p.milani@smatteo.pv.it
+390382502994

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion